drugset / Trial / NCT00593827
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to determine the effects of the weekly regimen of ixabepilone dosing compared to the once every 3 week dosing regimen in participants with metastatic breast cancer.
Timeline
- Start
- 2008-05
- Primary completion
- 2010-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ixabepilone | Small molecule | 16 mg/m2 | Intravenous |
| Comparator | Ixabepilone | Small molecule | 40 mg/m2 | Intravenous |